Global Market Study on Biologics Contract Manufacturing Demand: Strong Biologics Pipeline to Rapidly Surge Market Growth

Sep 2020| PMR1508A| Persistence Market Research

Report Highlights

Biologics Contract Manufacturing Demand - Scope of the Report

Persistence Market Research (PMR) recently published a market study on the global market for biologics contract manufacturing demand. The study provides detailed assessment on key market dynamics, including the drivers, trends, opportunities, restraints, and detailed information about the biologics contract manufacturing demand structure. The market study presents exclusive information about how biologics contract manufacturing demand will grow during the forecast period of 2020-2030.

Key indicators of market growth, which include Year-on-Year (Y-o-Y) growth of the market, and compounded annual growth rate (CAGR) are explained in PMR’s study in a comprehensive manner. This information can help readers understand the quantitative growth prospects of biologics contract manufacturing demand during the forecast period.

The study is relevant for stakeholders interested in biologics contract manufacturing demand, including biologics contract manufacturing service organizations, suppliers, distributors, and investors, and can help them in developing appropriate strategies to grow in the market. Stakeholders in biologics contract manufacturing demand, investors, industry experts, researchers, and journalists, as well as business researchers can leverage the information and data presented in PMR’s study.

The study also includes statistics as well as facts related to the macro- as well as micro-economic factors that are impacting developments in the market. It also offers actionable insights based on the future trends regarding biologics contract manufacturing demand. Furthermore, small businesses and new entrants related to biologics contract manufacturing demand too can make use of the information presented in this study, based on which, they can make appropriate business decisions to gain momentum in the market.

Key Questions Answered in PMR’s Biologics Contract Manufacturing Demand Study

  • How will CDMO services demand unfold over the coming years?
  • Which regions will continue to remain the most profitable regional markets for players dealing with biologics contract manufacturing demand?
  • Which factors will induce a change in biologics contract manufacturing demand during the assessment period?
  • How will changing trends impact biologics contract manufacturing demand?
  • How can market players capture the low-hanging opportunities related to biologics contract manufacturing demand in developed regions?
  • Which companies are leading in biologics contract manufacturing demand?
  • What are the winning strategies of stakeholders involved in biologics contract manufacturing demand services to upscale their position in this landscape?

Biologics Contract Manufacturing Demand: Research Methodology

In PMR’s study, a unique research methodology is utilized to conduct extensive research on the growth of biologics contract manufacturing demand, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the biologics contract manufacturing demand market study include statistics from government organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as a validation from companies dealing in biologics contract manufacturing demand, and makes PMR’s projections on the growth prospects of the market space more accurate and reliable.

  • Table 1 : Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 2 : Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 3 : Global Biologics Contract Manufacturing Demand Value (US$ Mn) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 4 : Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 5 : Global Biologics Contract Manufacturing Demand Value (US$ Mn) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 6 : Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 7 : Global Biologics Contract Manufacturing Demand Value (US$ Mn) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 8 : Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 9 : Global Biologics Contract Manufacturing Demand Value (US$ Mn) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 10 : Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Region
  • Table 11 : Global Biologics Contract Manufacturing Demand Value (US$ Mn) Analysis and Opportunity Assessment 2015-2030, By Region
  • Table 12 : North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Country
  • Table 13 : North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 14 : North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 15 : North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 16 : North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 17 : Latin America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 18 : Latin America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 19 : Latin America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 20 : Latin America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 21 : Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Country
  • Table 22 : Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 23 : Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 24 : Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 25 : Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 26 : South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Country
  • Table 27 : South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 28 : South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 29 : South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 30 : South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 31 : East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Country
  • Table 32 : East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 33 : East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 34 : East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 35 : East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 36 : Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Country
  • Table 37 : Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 38 : Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 39 : Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 40 : Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 41 : Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Country
  • Table 42 : Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 43 : Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 44 : Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 45 : Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 46 : U. S. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 47 : U. S. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 48 : U. S. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 49 : U. S. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 50 : Canada Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 51 : Canada Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 52 : Canada Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 53 : Canada Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 54 : U. K. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 55 : U. K. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 56 : U. K. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 57 : U. K. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 58 : Germany Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 59 : Germany Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 60 : Germany Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 61 : Germany Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 62 : France Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 63 : France Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 64 : France Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 65 : France Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 66 : Spain Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 67 : Spain Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 68 : Spain Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 69 : Spain Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 70 : Italy Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 71 : Italy Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 72 : Italy Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 73 : Italy Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Figure 1 : Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 2 : Global Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 3 : Commercial Contract Manufacturing Pricing Analysis (US$) for 1kL Batch Size, By Region, 2020
  • Figure 4 : Clinical Contract Manufacturing Pricing Analysis (US$) for 1kL Batch Size, By Region, 2020
  • Figure 5 : Global Biologics Contract Manufacturing Demand Value Analysis (US$ Mn), 2015-2019
  • Figure 6 : Global Biologics Contract Manufacturing Demand Value Forecast (US$ Mn), 2020-2030
  • Figure 7 : Global Biologics Contract Manufacturing Demand Absolute $ Opportunity, 2020 - 2030
  • Figure 8 : Global Biologics Contract Manufacturing Demand Share Analysis (%), By Product, 2020-2030
  • Figure 9 : Global Biologics Contract Manufacturing Demand Y-o-Y Analysis (%), By Product, 2020-2030
  • Figure 10 : Global Biologics Contract Manufacturing Demand Capacity Attractiveness Analysis By Product, 2020-2030
  • Figure 11 : Global Biologics Contract Manufacturing Demand Share Analysis (%), By Platform, 2020-2030
  • Figure 12 : Global Biologics Contract Manufacturing Demand Y-o-Y Analysis (%), By Platform, 2020-2030
  • Figure 13 : Global Biologics Contract Manufacturing Demand Capacity Attractiveness Analysis By Platform, 2020-2030
  • Figure 14 : Global Biologics Contract Manufacturing Demand Share Analysis (%), By Therapeutic Area, 2020-2030
  • Figure 15 : Global Biologics Contract Manufacturing Demand Y-o-Y Analysis (%), By Therapeutic Area, 2020-2030
  • Figure 16 : Global Biologics Contract Manufacturing Demand Capacity Attractiveness Analysis By Therapeutic Area, 2020-2030
  • Figure 17 : Global Biologics Contract Manufacturing Demand Share Analysis (%), By Application, 2020-2030
  • Figure 18 : Global Biologics Contract Manufacturing Demand Y-o-Y Analysis (%), By Application, 2020-2030
  • Figure 19 : Global Biologics Contract Manufacturing Demand Capacity Attractiveness Analysis By Application, 2020-2030
  • Figure 20 : Global Biologics Contract Manufacturing Demand Share Analysis (%), By Region, 2020-2030
  • Figure 21 : Global Biologics Contract Manufacturing Demand Y-o-Y Analysis (%), By Region, 2020-2030
  • Figure 22 : Global Biologics Contract Manufacturing Demand Capacity Attractiveness Analysis By Region, 2020-2030
  • Figure 23 : North America Biologics Contract Manufacturing Demand Capacity Share, By Product, 2020 (E)
  • Figure 24 : North America Biologics Contract Manufacturing Demand Capacity Share, By Platform, 2020 (E)
  • Figure 25 : North America Biologics Contract Manufacturing Demand Capacity Share, By Therapeutic Area, 2020 (E)
  • Figure 26 : North America Biologics Contract Manufacturing Demand Capacity Share, By Application, 2020 (E)
  • Figure 27 : North America Biologics Contract Manufacturing Demand Capacity Share, By Country, 2020 (E)
  • Figure 28 : North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 29 : North America Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 30 : North America Biologics Contract Manufacturing Demand Value Analysis (US$ Mn), 2015-2019
  • Figure 31 : North America Biologics Contract Manufacturing Demand Value Forecast (US$ Mn), 2020-2030
  • Figure 32 : Latin America Biologics Contract Manufacturing Demand Capacity Share, By Product, 2020 (E)
  • Figure 33 : Latin America Biologics Contract Manufacturing Demand Capacity Share, By Platform, 2020 (E)
  • Figure 34 : Latin America Biologics Contract Manufacturing Demand Capacity Share, By Therapeutic Area, 2020 (E)
  • Figure 35 : Latin America Biologics Contract Manufacturing Demand Capacity Share, By Application, 2020 (E)
  • Figure 36 : Latin America Biologics Contract Manufacturing Demand Capacity Share, By Country, 2020 (E)
  • Figure 37 : Latin America Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 38 : Latin America Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 39 : Latin America Biologics Contract Manufacturing Demand Value Analysis (US$ Mn), 2015-2019
  • Figure 40 : Latin America Biologics Contract Manufacturing Demand Value Forecast (US$ Mn), 2020-2030
  • Figure 41 : Europe Biologics Contract Manufacturing Demand Capacity Share, By Product, 2020 (E)
  • Figure 42 : Europe Biologics Contract Manufacturing Demand Capacity Share, By Platform, 2020 (E)
  • Figure 43 : Europe Biologics Contract Manufacturing Demand Capacity Share, By Therapeutic Area, 2020 (E)
  • Figure 44 : Europe Biologics Contract Manufacturing Demand Capacity Share, By Application, 2020 (E)
  • Figure 45 : Europe Biologics Contract Manufacturing Demand Capacity Share, By Country, 2020 (E)
  • Figure 46 : Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 47 : Europe Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 48 : Europe Biologics Contract Manufacturing Demand Value Analysis (US$ Mn), 2015-2019
  • Figure 49 : Europe Biologics Contract Manufacturing Demand Value Forecast (US$ Mn), 2020-2030
  • Figure 50 : South Asia Biologics Contract Manufacturing Demand Capacity Share, By Product, 2020 (E)
  • Figure 51 : South Asia Biologics Contract Manufacturing Demand Capacity Share, By Platform, 2020 (E)
  • Figure 52 : South Asia Biologics Contract Manufacturing Demand Capacity Share, By Therapeutic Area, 2020 (E)
  • Figure 53 : South Asia Biologics Contract Manufacturing Demand Capacity Share, By Application, 2020 (E)
  • Figure 54 : South Asia Biologics Contract Manufacturing Demand Capacity Share, By Country, 2020 (E)
  • Figure 55 : South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 56 : South Asia Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 57 : South Asia Biologics Contract Manufacturing Demand Value Analysis (US$ Mn), 2015-2019
  • Figure 58 : South Asia Biologics Contract Manufacturing Demand Value Forecast (US$ Mn), 2020-2030
  • Figure 59 : East Asia Biologics Contract Manufacturing Demand Capacity Share, By Product, 2020 (E)
  • Figure 60 : East Asia Biologics Contract Manufacturing Demand Capacity Share, By Platform, 2020 (E)
  • Figure 61 : East Asia Biologics Contract Manufacturing Demand Capacity Share, By Therapeutic Area, 2020 (E)
  • Figure 62 : East Asia Biologics Contract Manufacturing Demand Capacity Share, By Application, 2020 (E)
  • Figure 63 : East Asia Biologics Contract Manufacturing Demand Capacity Share, By Country, 2020 (E)
  • Figure 64 : East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 65 : East Asia Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 66 : East Asia Biologics Contract Manufacturing Demand Value Analysis (US$ Mn), 2015-2019
  • Figure 67 : East Asia Biologics Contract Manufacturing Demand Value Forecast (US$ Mn), 2020-2030
  • Figure 68 : Oceania Biologics Contract Manufacturing Demand Capacity Share, By Product, 2020 (E)
  • Figure 69 : Oceania Biologics Contract Manufacturing Demand Capacity Share, By Platform, 2020 (E)
  • Figure 70 : Oceania Biologics Contract Manufacturing Demand Capacity Share, By Therapeutic Area, 2020 (E)
  • Figure 71 : Oceania Biologics Contract Manufacturing Demand Capacity Share, By Application, 2020 (E)
  • Figure 72 : Oceania Biologics Contract Manufacturing Demand Capacity Share, By Country, 2020 (E)
  • Figure 73 : Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 74 : Oceania Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 75 : Oceania Biologics Contract Manufacturing Demand Value Analysis (US$ Mn), 2015-2019
  • Figure 76 : Oceania Biologics Contract Manufacturing Demand Value Forecast (US$ Mn), 2020-2030
  • Figure 77 : Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity Share, By Product, 2020 (E)
  • Figure 78 : Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity Share, By Platform, 2020 (E)
  • Figure 79 : Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity Share, By Therapeutic Area, 2020 (E)
  • Figure 80 : Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity Share, By Application, 2020 (E)
  • Figure 81 : Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity Share, By Country, 2020 (E)
  • Figure 82 : Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 83 : Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 84 : Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Value Analysis (US$ Mn), 2015-2019
  • Figure 85 : Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Value Forecast (US$ Mn), 2020-2030
  • Figure 86 : U. S. Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 87 : U. S. Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 88 : Canada Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 89 : Canada Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 90 : U. K. Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 91 : U. K. Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 92 : Germany Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 93 : Germany Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 94 : France Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 95 : France Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 96 : Spain Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 97 : Spain Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 98 : Italy Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 99 : Italy Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organization of all sizes.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report